BCR/ABL has a causal role in Philadelphia (Ph)-chromosome positive leukemia. The SH2/SH3 adapter protein CRKL is a major substrate of the deregulated BCR/ABL tyrosine kinase and is aberrantly tyrosinephosphorylated in Ph-positive leukemia cells. In this study, experiments were pursued to identify and analyse the CRKL phosphorylation site(s). In an in vitro kinase assay, CRKL phosphorylation by the abl kinase was limited to a small region between the two CRKL SH3 domains. Within this region, mutation of tyrosine residue 207 yielded a mutant CRKL which could not be phosphorylated by BCR/ABL. Stable overexpression of CRKL or CRKL-Y207F did not transform NIH3T3 cells, while the Y207F mutation eliminated tyrosinephosphorylation of CRKL. These studies indicate that Y207 in CRKL represents the major in vivo phosphorylation site. Phosphorylation of Y207 provides a binding site for the CRKL SH2 domain and potentially for other SH2-containing proteins. The Y207F mutation in CRKL did not enhance or decrease association with various target signalling proteins, including SOS or C3G, which interact speci®cally with the CRKL N-SH3 domain. These ®ndings suggest that complex formation with cellular targets is not modulated by CRKL tyrosinephosphorylation.
Introduction
Chronic myelogenous leukemia (CML) and some acute lymphoblastic leukemias (ALL) are characterized by the reciprocal chromosomal translocation t(9;22), in which exons from the bcr gene are fused to exons of the c-abl gene van Etten, 1993) . The generation of BCR/ABL is considered the initial event in the development of Phpositive leukemia, since this chimeric gene has been shown to induce leukemia in mice (Daley et al., 1990; Heisterkamp et al., 1990) . In BCR/ABL, deregulation of the ABL tyrosine kinase is essential for its oncogenic activity (Konopka et al., 1984; Lugo et al., 1990) . In recent years, a number of proteins have been reported to be associated with BCR/ABL and/or to be phosphorylated by it. Determining how this modi®cation aects their function and their corresponding signaling pathways, is the key to unravelling the mechanisms of BCR/ ABL-induced leukemogenesis.
CRKL is a 38 kDa protein comprised of an SH2 domain followed by two SH3 domains (ten Hoeve et al., 1993) and shares a high degree of homology with cCrk, a proto-oncogene (Mayer et al., 1988; Matsuda et al., 1992) . Mouse Crkl is ubiquitously expressed and mainly detectable as the non-tyrosine phosphorylated isoform, except for in lung and fetal tissues, in which substantial amounts of Crkl P are present (de Jong et al., 1995a) . The CRKL SH2 domain binds to speci®c phosphotyrosine residues in paxillin (Salgia et al., 1995) and in c-CBL (de Jong et al., 1995b) . In analogy to c-Crk, the N-terminal SH3 domain of CRKL can interact with proline-rich binding sites in c-ABL, SOS (ten Hoeve et al., 1994a; de Jong et al., 1995b) and C3G . These ®ndings implicate a normal function of CRKL upstream in the signaling pathways of small GTPases of the extended ras family.
The SH2-SH3 adaptor molecule CRKL could be an important mediator of the leukemogenic activity of BCR/ABL, since it is prominently and abnormally tyrosine-phosphorylated in BCR/ABL-expressing cell lines and in Ph-positive CML and ALL patient material (ten Hoeve et al., 1994a,b; Nichols et al., 1994; Oda et al., 1994) . In addition, Crkl is aberrantly phosphorylated in leukemic tissues of BCR/ABLtransgenic mice (de Jong et al., 1995a) , and it associates with BCR/ABL in CML cell lines and BCR/ABL-transfected cells (ten Hoeve et al., 1994a,b) . The SH2 domain of CRKL can serve as a docking site for other targets phosphorylated on tyrosine by BCR/ABL, such as c-CBL (de Jong et al., 1995b) , a proto-oncoprotein which is involved in the transformation of haematopoietic cells (Andoniou et al., 1994) . In v-abl or BCR/ABL-transformed cells, c-CBL is also bound to the SH2 domains of the p85 subunit of phosphatidylinositol-3' kinase (PI3K), thereby elevating the PI3K activity (Sattler et al., 1996) . In BCR/ABL-transformed cells, the CRKL-SH2 domain also binds to the focal adhesion protein paxillin which is involved in integrin signaling (Salgia et al., 1995) . These ®ndings demonstrate that CRKL is a prominent link between the BCR/ABL tyrosine kinase and other possible downstream eectors.
Little is known about the function of CRKL phosphorylation, and the exact residues that are aected. Its prominent and abnormal phosphorylation in CML suggests a key role in BCR/ABL-induced leukemia, and therefore we set out to identify the site(s) in CRKL phosphorylated by BCR/ABL. Here we report that residue 207 is the sole tyrosine residue phosphorylated by BCR/ABL in vivo, as well as the major phosphorylation site in absence of BCR/ABL. We further show that phosphorylation of tyrosine 207 is unlikely to aect the binding of CRKL with CRKLassociating proteins.
Results

Characterization of in vitro tyrosine-phosphorylation sites in Crkl
To determine the approximate location of the Abl-kinase substrate sites in Crkl, we used a bacterially produced trpE-v-abl protein (Stam et al., 1987) in an in vitro kinase assay to phosphorylate CRKL. The kinase domain of abl in trpE-v-abl is¯anked at its N-terminus by an SH2 domain with a minute N-terminal truncation and at its Cterminus by a proline-rich region containing a conserved SH3-binding site. In c-Abl, this has been shown to bind with several SH3-containing adaptor proteins, including Crk (Ren et al., 1994) and Crkl (ten Hoeve et al., 1994a) . Bacterial extracts containing active trpE-v-abl were incubated with puri®ed GST-CRKL fusion proteins and g-ATP as substrates and subsequent phosphorylation was monitored by autoradiography ( Figure 1a ). Similar amounts of proteins were used, as checked by Coomassie staining of the protein gel (data not shown). GST-CRKL proteins containing the spacer region between the two SH3 domains were eciently phosphorylated by the abl kinase, whereas the GST-CRKL SH2SH3(N) protein lacking this sequence was not (Figure 1a and b) . Notably, in this assay, CRKL phosphorylation did not require the stable binding to the abl kinase since GST-CRKL SR lacks the N-terminal SH3 domain which mediates the binding to Abl, but is nonetheless phosphorylated. Although GST contains several tyrosine residues, these were not phosphorylated, indicating the substrate speci®city of the abl kinase. These data demonstrated that Abl phosphorylation of CRKL occurs in a region spanning amino acid residues 195 to 247. Figure 1 Localization of the abl kinase phosphorylation site in human CRKL. (a) Phosphorylation of puri®ed GST-CRKL fusion proteins by abl kinase was analysed by an in vitro kinase assay using bacterially produced trpE-v-abl and [ 32 P-g]ATP as a substrate. GST-proteins were resolved by SDS ± PAGE and phosphorylated products were visualized by autoradiography. The numbers in brackets above the lanes refer to the CRKL residues fused to GST. (b) Schematic structure of GST fusion proteins used in (a) and summary of phosphorylation of CRKL sequences by the abl kinase. The solid line indicates the GST moiety, the open box represents the SH2 domain. The stippled boxes depict the amino-terminal and carboxy-terminal SH3 domains, respectively. The numbers below the schematic representation of CRKL refer to amino acid residues in human CRKL (ten Hoeve et al., 1993) . Plus or minus indicate whether GST-fusion protein is a substrate for abl kinase (c) Sequence comparison of human CRKL and CRKII in the region phosphorylated by abl. Two tyrosines present in human CRKL are putative substrates and are indicated by an arrowhead. Identical amino acids in CRKII are shown by dots. Gaps have been introduced to optimize similarity and are indicated by dashes latter is similar to Y221 in Crk, a phosphorylation site of c-Abl Figure 1c) . The in vitro optimal substrate site of ABL, EAIYAAPF, has been determined with a degenerate peptide library (Songyang et al., 1995) and, in critical positions, this site is conserved in CRKL. The two possible tyrosine phosphorylation sites in CRKL were subsequently mutated, resulting in the substitution to phenylalanine. Single and doubly mutated CRKL proteins were transiently expressed in transfected COS cells ( Figure  2a ). Expression levels were similar for all CRKL proteins, but the mutant proteins displayed a faster migration in SDS-PAA gels as compared to unmutated CRKL ( Figure 2a ; lane 2 vs lanes 3 ± 5). When COS cells co-expressed CRKL or CRKL-Y198F and BCR/ ABL, a double CRKL band appeared, of which the upper band represents the tyrosine-phosphorylated CRKL protein, as detected by phosphotyrosine antibodies (Figure 2b ; lanes 6 and 9). Co-transfection of BCR/ABL and mutant CRKL-Y207F or CRKL-Y198/207F did not yield tyrosine-phosphorylated CRKL ( Figure 2b ; lanes 7 and 8). Thus, residue Y207 is tyrosine-phosphorylated by BCR/ABL in COS-1 cells.
In agreement with our previous ®ndings, in cells overexpressing CRKL together with P210, P210 was found in complex with CRKL ( Figure 2c ). The Y207F and Y198F mutation did not visibly aect the binding to P210, since the amount of co-precipitated P210 ( Figure 2c ; lanes 6 ± 9) are in agreement with the P210 expression levels in the extracts ( Figure 2c ; lanes 2 ± 5). These results indicate that the lack of phosphorylation in the Y207F mutant is not due to an impaired binding of P210 to the mutated CRKL.
The quantity of CRKL P is dependent on the amount of BCR/ABL. For example, in Figure 2b , lane 9, a reduced expression results in a reduced amount of phosphorylated CRKL (Figure 2b , and data not shown). This con®rms our previous observation that in the leukemic cells of Ph-positive leukemia patients, CRKL phosphorylation is correlated with the level of BCR/ABL expression (ten Hoeve et al., 1994b) .
Tyrosine 207 is the major in vivo phosphorylation site
To study the function of the CRKL Y207 phosphorylation site in a cell type which is not morphologically transformed, stably expressing NIH3T3 cell lines were generated by transfecting expression constructs for CRKL or CRKL-Y207F together with a plasmid containing the neomycin-resistance gene. Several neomycin resistant clones were isolated that expressed signi®cant amounts of CRKL: 10-to 20-fold more CRKL or CRKL-Y207F as compared to endogenous Crkl. 3T3-C, clones #1 and #5, and 3T3-Cmut, clones #4 and #5, expressed human CRKL and CRKL-Y207F, respectively (Figure 3a ; lower panel), and are representative clones chosen for further study. None of these or other clones developed a change in cellular morphology as compared to the parental cell line or grew into foci after reaching con¯uency (data not shown). In accordance, no obvious changes were observed in cellular tyrosine-phosphorylated protein levels on a Western blot (Figure 3a ; upper panel).
To accurately assess the phosphorylation status of CRKL in these cell lines, it was immunoprecipitated from cellular extracts. CRKL immunoprecipitates were analysed on a Western blot probed with antiphosphotyrosine antibodies (Figure 3b ). In the stable 3T3 cell lines 3T3-C1, more tyrosine-phosphorylated CRKL was detected compared to the parental cell line NIH3T3, whereas 3T3-Cmut4 cells contained an amount of CRKL P similar as found in NIH3T3 cells (Figure 3b ; upper panel). For comparison, the P210BCR/ABL-expressing CML cell line K562 was included, which contains considerably higher expression levels of tyrosine-phosphorylated CRKL, since CRKL is ampli®ed 5-to 10-fold in this cell line (ten Hoeve et al., 1993 (ten Hoeve et al., , 1994a . Since similar amounts of overexpressed CRKL and CRKL-Y207F were precipitated (Figure 3b ; lower panel), this cannot account for the observed dierences in levels of CRKL phosphorylation (Figure 3b ; upper panel). Thus, the Y207F mutation also abolishes CRKL phosphorylation by endogenous cellular tyrosine kinases, indicating that tyrosine 207 is the major tyrosine-phosphorylation site in vivo.
The Y207F mutation does not aect the association of CRKL with target proteins
The phosphorylation status of tyrosine 207 in CRKL provides a possible mechanism for regulating its interaction with other cellular proteins. We therefore studied whether the mutation of Y207 in CRKL aects binding to signaling proteins that interact speci®cally with the CRKL N-SH3 domain. These include the guanine exchange factors for ras and rap1, SOS and C3G, respectively, and the oncoprotein BCR/ABL (ten Hoeve et al., 1994a; de Jong et al., 1995b; Feller et al., 1995) . We also examined c-CBL, which speci®cally binds to the SH2 domain in CRKL when phosphorylated on tyrosine (de Jong et al., 1995b) .
CRKL was immunoprecipitated from extracts of COS cells overexpressing combinations of CRKL or CRKL-Y207F with or without co-transfection of P210 BCR/ABL . Comparable overexpression levels of CRKL and CRKL-Y207F were detected in transfected COS cells, both in the absence and in the presence of P210 (data not shown). Comparable levels of overexpressed CRKL and CRKL-Y207F were present in CRKL immunoprecipitates (Figure 4f ). Co-expression of P210 resulted in the generation of considerable amounts of CRKL P , up to 50% of the overexpressed CRKL (see Figure 2 and data not shown).
As shown in Figure 2c , the Y207F mutation did not reduce binding to P210: similar amounts of coprecipitated BCR/ABL were detected for CRKL and CRKL-Y207F precipitates (Figure 4a ; compare lanes 7 and 8). The 29 kDa adaptor protein GRB-2 was coprecipitated with CRKL antisera only in cells coexpressing P210 (Figure 4g ; lanes 7 and 8). However, no GRB-2-CRKL or -CRKL-Y207F complexes were detectable in the absence of P210 (Figure 4g ; lanes 4 ± 6).
Only very low levels of SOS (i.e. only visible after prolonged exposure; data not shown) were detectable in CRKL precipitates from untransfected COS cells, which contain only endogenous Crkl. However, SOS was found in complex with overexpressed CRKL and CRKL-Y207F, at comparable levels and regardless whether P210 was co-expressed ( Figure 4b ; lanes 5 ± 8). In contrast, C3G was readily detectable in complex with endogenous Crkl in mock-transfected COS cells (Figure 4c; lane 4) . Similar as to SOS, overexpression of CRKL markedly augmented the association of CRKL and C3G, and again, neither the Y207F mutation, nor the presence of P210 had any visible eect on the level of complex formation (Figure 4c) .
The binding of CRKL to CBL was not impaired by the Y207F-mutation. P210 overexpression did not increase the amount of CBL associated with CRKL (Figure 4d ), because it also did not increase the levels of tyrosine-phosphorylated CBL. This may be explained by the already high levels of endogenous tyrosine-phosphorylated CBL present in the transformed COS-1 cells (data not shown). The amount of co-precipitated p85 subunit of PI3K followed the levels of CBL in the CRKL precipitates, in accordance with the reported association of these molecules (Sattler et al., 1996) . These results demonstrate that the phosphorylation state of residue Y207 of CRKL does not noticeably in¯uence the quantitative association between CRKL and proteins found to interact with CRKL.
Discussion
Throughout murine embryogenesis, many tissues demonstrate the presence of Crkl P , suggesting a role for phosphorylated Crkl in cellular growth or dierentiation, and this is consistent with the highly restricted expression of phosphorylated Crkl in adult tissues (de Jong et al., 1995a) . Nevertheless, this does not exclude the possibility of transient tyrosinephosphorylation of Crkl in the adult tissues. Although to date, several cytokines and growth factors have been tested, none were capable of inducing CRKL phosphorylation in hematopoietic cells (Oda et al., 1994; Nichols et al., 1994) .
We demonstrate here that Y207 is the major in vivo phosphorylation site used by (a) cellular tyrosine kinase(s) that can phosphorylate CRKL under normal conditions, since the mutation abrogates the phosphorylation of overexpressed CRKL in ®broblast cells. One obvious candidate for such kinase is c-Abl, which can interact with CRKL through its proline-rich region containing several SH3 binding sites (Ren et al., 1994 and unpublished results). However, it remains possible that Crkl is a substrate for (an)other as of yet unidenti®ed kinase(s). For example, signaling through the membrane-bound IGF-1 tyrosine-kinase receptor is a possible pathway leading to in vivo Crkl phosphorylation, because activation of the IGF-1 receptor was reported to substantially increase the intracellular phosphorylation of the related Crk proteins in several cell lines (Beitner-Johnson and LeRoith, 1995) . The elucidation of signals leading to and the cellular tyrosine kinases responsible for the in vivo phosphorylation of Crkl at Y207 will likely unveil the functional signi®cance of this modi®cation in a normal cellular context.
We have previously reported that CRKL is the major tyrosine-phosphorylated protein in peripheral blood cells of CML patients expressing an active BCR/ ABL protein (ten Hoeve et al., 1994b) . The data presented here demonstrate that tyrosine residue 207 in CRKL is the sole tyrosine-phosphorylation target for the deregulated Abl kinase in BCR/ABL.
To obtain insight into the role of CRKL phosphorylation on BCR/ABL-induced leukemia, we examined the eect of a phosphorylation-defective CRKL mutant on its binding to known cellular targets in the presence of BCR/ABL. Known targets include those speci®cally interacting with the N-terminal SH3 domain and those binding to the SH2 domain. CRKL has been shown to associate in vivo with the guanine nucleotide releasing factors SOS, (ten Hoeve et al., 1994a) , an activator of ras (Egan et al., 1993; RozakisAdcock et al., 1993) , and C3G Sawasdikosol et al., 1995) through its SH3 domain. C3G is an activator of GTPase Rap1, which is a suppressor of ras transformation (Gotoh et al., 1995) . Furthermore, Rap1 has a crucial role in the process of superoxide formation in neutrophils (Maly et al., 1994) . C3G was originally identi®ed as a CRKbinding protein and contains several binding sites for the Crk N-SH3 domain (Tanaka et al., 1994; Knudsen et al., 1994) . Despite the high anity of Crk for C3G in vitro , CRK is not complexed in vivo with C3G in T-cells, whereas CRKL is (Sawasdikosol et al., 1995; Reedquist et al., 1996) . This provides a ®rst example of dierent biological roles for these related adaptor molecules. In agreement with this, our results show a constitutive interaction of endogenous Crkl with C3G in COS cells.
In contrast, hardly any SOS was detectable in complex with endogenous CRKL, although overexpressed CRKL was associated with SOS. The binding preference of the CRKL N-SH3 domain is likely to be similar to that of CRK. The CRK N-SH3 domain recognizes binding sites characterized by APXLPXK, which occur multiple times in C3G . Although similar SH3 binding sites are present in SOS, these possess a lower anity because of a conservative substitution at a critical position, which can explain the observed dierence between the association of endogenous Crkl with C3G and SOS.
We considered one possible model of regulation in which the interaction between CRKL and the exchange factors SOS and C3G is regulated through phosphorylation: tyrosine-phosphorylation of CRKL could have weakened or abrogated the stability of existing complexes or increased complex formation between these proteins. Phosphorylation as a mechanism of regulation is exempli®ed by the interaction between GRB-2 and SOS: serine/threonine phosphorylation of SOS by activation of the ERK pathway causes dissociation of the GRB-2/SOS complex (Waters et al., 1995) . However, our results clearly demonstrate that the tyrosine-phosphorylation of CRKL does not in¯uence the formation or stability of complexes it forms with C3G or SOS. The possibility remains that tyrosine phosphorylation of CRKL modulates the exchange factor activity of the C3G or SOS bound to CRKL.
Tyrosine phosphorylation of CRKL creates a putative binding site for SH2 domains. Interestingly, the phosphorylation sites in Crkl and Crk resemble preferential binding sites for their own SH2 domains (Songyang et al., 1993) . For crk, a model in which intramolecular folding takes place has been proposed, since phosphorylated Y221 can bind to its SH2 domain in vitro Rosen et al., 1995) . As a consequence, phosphorylated Crk is blocked in vitro in its intermolecular interactions occurring through the N-SH3 domain . Thus, phosphorylation of Crk provides a possible regulatory mechanism for Crk function in vivo. However, the in vivo data in transfected COS cells presented here do not favor a similar model in which CRKL is rendered inactive by phosphorylation, since the CRKL-Y207F mutant did not show a higher degree of association with the CRKL SH3 domain binding proteins.
Neither CRKL nor CRKL-Y207 was found in complex with the adaptor molecule GRB-2. Interestingly, when co-expressed with BCR/ABL, GRB-2 did appear in CRKL immunoprecipitates. The co-precipitation of GRB-2 in cells co-expressing BCR/ABL and the CRKL-Y207 mutant rules out the possibility of a CRKL-P/GRB-2 SH2 binding. In view of the fact that GRB-2 has been shown to bind to tyrosine-phosphorylated residue Y177 in the BCR moiety of BCR/ABL, that it can complex with the ABL moiety in vitro, and that it can associate with BCR/ABL through SHC or CRKL bound c-CBL (Puil et al., 1994; Pendergast et al., 1994; Tauchi et al., 1994; de Jong et al., 1995a; Fukazawa et al., 1995) we conclude that the GRB-2 detected in CRKL immunoprecipitates results from GRB-2 bound directly or indirectly to BCR/ABL.
The eminent phosphorylation of CRKL during development and in the pathogenesis of Ph-positive leukemia is well established. In the current study, we further de®ned the process of CRKL phosphorylation. Additional studies to shed light on the functional relevance of CRKL phosphorylation remain necessary. One way to investigate this is to determine if the Y207 mutant can reverse the phenotype of BCR/ABL transformed cell lines. Another intriguing possibility is that phosphorylated tyrosine residue 207 becomes a binding site for an as of yet unidenti®ed SH2-containing factor, which may transduce the oncogenic signal from BCR/ABL. The latter possibility, as well as the potential of CRKL-Y207F to reverse BCR/ABL transformation are currently under investigation.
Materials and methods
Cells and transfections
COS-1 cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Gibco/BRL). NIH3T3 cells were cultured in DMEM containing 10% calf serum (Gibco/BRL). Transient expression of proteins was obtained by introducing plasmids into COS-1 cells using the DEAEdextran method essentially as described in Okayama and Berg (1983) . Cells were harvested 72 h post transfection. For stable expression of proteins, NIH3T3 cells were transfected with the expression vectors together with pMAMneo (Clontech), encoding the neomycin-resistance gene, according to the calcium phosphate precipitation method. After 10 ± 14 days, colonies surviving selection on Geneticin (Gibco/BRL) were isolated and propagated for further study.
Antibodies and antisera
Polyclonal rabbit anti-Cbl and anti-crk-L were purchased from Santa Cruz Biotechnology. Anity-puri®ed CRKL antibodies have been described (de Jong et al., 1995a) . For detection of immunoprecipitated CRKL proteins, biotinylated CRKL antibodies were prepared following a standard protocol (Harlow and Lane, 1988) . Antiphosphotyrosine (PY20) and anti-Grb2 monoclonal antibodies were obtained from Transduction Laboratory; antiBcr (AB-2) and anti-phosphotyrosine antibodies (AB-2) were from Oncogene Science, Inc. Polyclonal anti-C3G sera was a kind gift from BS Knudsen (Rockefeller University, New York, NY). Antip85 sera and anti-SOS antibodies were from Upstate Biotechnology, Inc.
Plasmid constructs
The SG5-derived plasmid SG-CRKL carrying the cDNA of human CRKL has been described elsewhere (ten Hoeve et al., 1994a) . Site-directed mutagenesis was accomplished according to the method of Deng and Nickolo (1992) . Single point mutations were introduced in the second codon base, changing tyrosines 198 and 207 into phenylalanine. Mutated cDNA was checked for the absence of other introduced mutations by sequencing. Wild type sequence in SG-CRKL was replaced by mutated sequences using standard recombinant DNA procedures (Sambrook et al., 1989) , generating plasmids SG-CRKL-Y198F, -Y207F and -Y198/207F. Bacterial expression vectors for production of the various GST-CRKL subdomain proteins have been described (ten Hoeve et al., 1994a; de Jong et al., 1995b) , except for GST-CRKL SH2SH3 (N), which was produced by inserting a 550 bp TaqI-EcoRI fragment of the human CRKL cDNA into pGEX-2T. GST-CRK SH3SH3 carrying the mouse c-Crk sequence was kindly provided by S Feller (Rockefeller University, New York, NY). The bacterial expression vector trpE-v-abl contains a 1.2 kb HincII-PstI fragment and produces a v-abl kinase (Stam et al., 1987) .
Preparation of GST-fusion proteins, trpE-v-Abl extract and in vitro kinase assay Expression and puri®cation of GST-fusion proteins was performed as described (Smith and Johnson, 1988) . Proteins were dialyzed against 20 mM Tris-HCl, pH 8.0, 50 mM NaCl, 10% (v/v) glycerol. TrpE-v-abl protein was produced in E. coli strain RR1 as described previously (Stam et al., 1987) . Bacterial lysates containing active kinase enzyme were prepared by sonication of cells in 10 volumes of 20 mM TrisHCl, pH 8.0, 2 mM EDTA, 100 mM NaCl, 10 mM bmercaptoethanol. Bacterial lysate was centrifuged at 20 000 g for 20 min. In vitro kinase reactions were performed in 20 ml reaction volumes containing 7 mM GSTfusion protein, 0.5 ml bacterial extract, 25 mM Tris-HCl, pH 8.0, 10 mM MgCl 2 , 1 mM DTT, 0.5 mM ATP, 10 mCi [ 32 Pg]ATP and were incubated for 30 min at 308C. Reactions were stopped by adding SDS-sample buer and were loaded on 10% SDS-PAA gels.
Immunoprecipitation and immunoblot analysis
Using previously described methods (ten Hoeve et al., 1994a) , transfected cells or cell lines were washed twice with PBS and were lysed immediately in Triton-lysis buer (25 mM Na-phosphate, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, 50 mM NaF, 10 mg/ml aprotinin and leupeptin, 1 mM Na 3 VO 4 and 1 mM PMSF). 0.25 ± 1.0 mg lysate proteins were used for immunoprecipitations. Proteins were separated by SDS ± PAGE and electrophoretically transferred to Immobilon-P membranes (Millipore Corp). Western blots were incubated with antibodies as described (ten Hoeve et al., 1994a) and visualised with ECL reagents (Amersham).
